|Bid||36.00 x 800|
|Ask||41.00 x 900|
|Day's range||33.58 - 36.96|
|52-week range||27.65 - 133.82|
|Beta (5Y monthly)||0.69|
|PE ratio (TTM)||N/A|
|Earnings date||03 Aug 2022 - 08 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||123.00|
PALO ALTO, Calif., May 21, 2022--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced data showing its blood-based multimodal test achieved clinically significant thresholds of sensitivity and specificity in detecting colorectal cancer (CRC). These data were presented during an oral presentation at Digestive Disease Week 2022.
The recent price decline of 49% in Guardant Health, Inc.'s ( NASDAQ:GH ) stock may have disappointed insiders who...
Shares of Guardant Health (NASDAQ: GH) were trading 23.4% lower as of 11:51 a.m. ET on Friday. The steep decline came after the company announced its first-quarter results following the market close on Thursday. This result was in line with Wall Street estimates.